Dr. James Forsythe, a Member of HST Global’s Board of Directors and Scientific Advisory Board, Featured in Suzanne Somers’ New Book Knockout

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced that James W. Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Scientific Advisory Board, has been featured in Suzanne Somers’ new book Knockout.

“Cancer’s an epidemic… and yet we keep going back to the same old pot, because it’s all we’ve got. Well, this is a book about options.”

In Knockout, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments—treatments that build up the body rather than tear it down. Somers herself has stared cancer in the face, and a decade later she has conquered her fear and has emerged confident in the path she has chosen.

Ms. Somers shares her personal choices and outlines an array of options from doctors across the country which includes effective alternative treatments without chemotherapy, radiation and sometimes eliminating surgery. She also explores integrative protocols that combine standard treatments with therapies that build up the immune system and outlines methods for managing cancer to truly live with the disease. Since prevention is the best course, Doctors interviewed in Knockout provide nutrition, lifestyle, and dietary supplementation options to help protect you from contracting the disease in the first place.

Ms. Somers is quoted by the AP as stating of her latest book in an interview, “Cancer’s an epidemic… and yet we keep going back to the same old pot, because it’s all we’ve got. Well, this is a book about options.” Dr. Forsythe further stated, “For years I have dedicated my practice to offering cancer patient’s traditional oncology as well as science-based integrative treatment options. I am honored that Ms. Somers has chosen to interview me and highlight my work in her new book.”

Mr. Ron Howell, CEO and President of HST Global Inc., stated, “We are impressed with Ms. Somers’ latest book, Knockout. Her passion, experience, and personal commitment to alternative methods in treating cancer are evident throughout her writings and she has worked hard to validate treatment alternatives for this life threatening disease. We are pleased that she has dedicated a chapter in her new book to a member of our Company. This is further confirmation of the strategic direction that both Dr. Forsythe and HST Global have taken in providing alternative health care options for those who are suffering from late stage cancer.”

Wes Tate, CFO, stated “I am excited about the fact that Dr. Forsythe and HST Global’s protocols have now moved into the national spotlight and how this news can benefit our shareholders in both their personal and economic interests. We continue everyday to substantiate shareholder value through pioneering new technologies that enhance quality of life.”

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.